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ABSTRACT
Omenn syndrome (OS) is a form of severe combined immunodeficiency (SCID) characterized by erythroder-
mia, hepatosplenomegaly, lymphadenopathy, and alopecia. In patients with OS, B cells are mostly absent, T-
cell counts are normal to elevated, and T cells are frequently activated and express a restricted T-cell receptor
(TCR) repertoire. Thus far, inherited hypomorphic mutations of the recombination activating genes either 1 or 2
(RAG12) have been detected in most OS patients. We have recently experienced a rare case of OS showing
the revertant mosaicism due to multiple second-site mutations leading to typical OS clinical features with RAG1
-deficient SCID. In this review, we will focus on the variation of several phenotypes of OS.
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INTRODUCTION
The common characteristic of severe combined im-
munodeficiency (SCID), a group of rare monogenic
disorders, is the occurrence of a block in T cell differ-
entiation, always associated with a direct or indirect
impairment of B cell immunity.1,2 The resulting com-
bined immunodeficiency is responsible for the clini-
cal severity of SCID, which, without treatment, leads
to death within the first year of life. At least, eleven
distinct SCID phenotypes have been identified to
date. Mutations of several genes have been found to
cause SCID as shown in Table 1. Identifying the
pathophysiological basis of most SCID conditions has
led to the possibility of molecular therapy as an alter-
native to allogeneic hematopoietic stem cell trans-
plantation.
Omenn syndrome (OS ) , was first reported by
Omenn in 1985, one of a rare SCID characterized by
the presence of a substantial number of oligoclonal,
activated T cells, and the lack of B lymphocytes, asso-
ciated with particular clinical features such as gener-
alized erythroderma , lymphadenopathy , hepa-
tosplenomegaly , and increased occurrence of life-
threatening infections.3
In OS patients, circulating B lymphocytes are usu-
ally absent , whereas various numbers of activated
and oligoclonal T lymphocytes are present in periph-
eral blood and infiltrate the skin , gut , liver and
spleen, causing a graft-versus-host-like disease.4-7 OS
is caused by mutations of the recombination activat-
ing genes (RAG1 and RAG2) 2 that are essential for V
(D) J recombination. 8,9 Unless treated with hema-
topoietic stem cell transplantation, OS patients usu-
ally succumb early in life to overwhelming opportun-
istic infections.7
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Bearing geneDiagnosisPhenotypes
ADAADA deficiencyT (－) B (－) NK (－) SCID
RAG1, RAG2RAG1, RAG2 deficiencyT (－) B (－) NK (＋) SCID
ArtemisArtemis deficiency
gc chainX-SCIDT (－) B (＋) NK (－) SCID
Jak3Jak3 deficiency
CD45CD45 deficiency
IL-7RaIL-7Ra deficiencyT (－) B (＋) NK (＋) SCID
RAG1, RAG2Omenn syndromeT (＋) B (－) NK (＋) SCID
ADA; adenosine deaminase, SCID; severe combined immunodeficiency
RAG; recombination activating genes
Table 1 Major phenotypes of SCID
OthersOutcomeMutationClinical Feature
Age at Di-
agnosis
Case
Typical Omenn 
syndrome
Dead at 5 mRAG1; R396C, 
L885R
Hepatosplenomegaly, lymphnode sweling, 
eczema, eosinophilia, IgE elevation
2 m1＊
Typical Omenn 
syndrome
Dead at 21 
days
RAG1; R396C, 
L885R
Hepatosplenomegaly, lymphnode sweling, 
eczema, eosinophilia, IgE elevation
0 m2＊
Materno-fetal 
transplantation
post BMT, live 
at 10 y
RAG1; R559S, 
R897stop
Lymphnode sweling, eczema, eosinophilia, 
IgE elevation
4 m3
Typical Omenn 
syndrome
post SCT, live 
at 2 y 10 m
RAG2; A73H, 
Q258stop
Hepatosplenomegaly, lymphnode sweling, 
eczema, eosinophilia, IgE elevation
0 m4
Atypical Omenn 
syndrome
post BMT, live 
at 2 y 11 m
RAG1; R142stop, 
R396H
Poor growth weight, respiratory distress10 m5
2nd site mutations
post SCT, live 
at 1y 8 m
RAG1; del 2441 
framshift
Hepatosplenomegaly, eczema, eosinophilia
3 m6
SCT; stem cel transplantation, BMT; bone marow transplantation, m; month, y; year＊sibling
Table 2 Clinical features of six cases of RAG1/RAG2 mutaitons in Japan
SEVERAL PHENOTYPES OF OMENN SYN-
DROME
SCID represent a heterogeneous group of hereditary
defects of the immune system that affect both T and
B cells and whose etiology has only recently begun to
be understood. A portion of these SCID patients bear
a defect in either of the two recombination-activating
genes, RAG1 or RAG2,4 while others have mutations
in a newly identified gene, Artemis.10
OS is an unusual severe immunodeficiency with T
cells but no B cells, and peculiar features also due to
a defect in RAG1 or RAG2 genes.8,9 All these three
forms are characterized by an impairment of the V
(D) J recombination, the process that insures the so-
matic diversification of immunoglobulin and T cell
receptor-encoding genes . Recent findings have en-
abled us to better understand the pathophysiology of
these three immunodeficiencies, which affect the V
(D) J recombination process to a different extent and
in different ways. Villa et al. reported the clinical and
immunological observations of V (D) J recombination
defects in lymphocytes due to RAG mutations.5 They
analyzed 44 such patients from 41 families, and con-
cluded that:(1) null mutations on both alleles lead to
the T-B-SCID phenotype ; ( 2 ) patients manifesting
classic OS have missense mutations on at least one al-
lele and maintain partial V (D) J recombination activ-
ity, which accounts for the generation of residual, oli-
goclonal T-lymphocytes;(3) in a third group of pa-
tients , findings were only partially compatible with
OS, and these patients, who also carried at least one
missense mutation, may be considered to have atypi-
cal SCIDOS;(4) patients with engraftment of mater-
nal T cells as a complication of a transplacental trans-
fusion represented a fourth group, and these patients,
who often presented with a clinical phenotype mim-
icking OS, may be observed regardless of the type of
RAG gene mutation. These results suggest that clini-
cal and immunologic phenotypes of patients bearing
RAG mutation are more diverse than previously re-
ported and that this diversity is related to the specific
type of RAGmutation.
OUR RECENT CASE AND REVIEW OF
RAG1RAG2 MUTATIONS IN JAPAN
Recently , we encountered a 3-month-old boy with
generalized exudative erythrodermia , hepa-
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Fig. 1 Various phenotypes of Omenn syndrome. Omenn syndrome (OS) shows various 
phenotypes. Typical OS has the generation of residual RAG activity, resulting in oligoclonal ex-
pansion of autoreactive T cels (Typical Omenn). Atypical OS may result if expansion of activat-
ed, oligoclonal T cels do not become predominant. As shown in OS with MFT, patients with 
engraftment of maternal T cels as a complication of a transplacental transfusion often pre-
sented with a clinical phenotype mimicking OS, and may be observed regardless of the type of 
RAG gene mutation. Our case showed oligoclonal expansion of T lymphocytes with multiple 
second-site mutations leading to typical OS with RAG1-deficient SCID shown in B- T- SCID 
with reversions.
Normal
RAG
B T
RAG
B T
IgE
T
RAG
IgE
RAG
B MFT
RAG
B T
Polyclonal
B cells
Polyclonal
T cells
Oligoclonal
T cells
Oligoclonal expansion
of alloreactive T cells
Typical OmennB- T- SCID
Absence of mature 
B or T cells
Oligoclonal expansion
of autoreactive T cells
B- T-SCID
 with reversionsOmenn with MFTAtypical Omenn
Oligoclonal expansion of
 autoreactive T cells with
 multiple reversions
tosplenomegaly, draining otitis externa, and alopecia,
with a history of Pseudomonas aeruginosa bactremia
requiring systemic antibiotic treatment . Laboratory
evaluation found mild anemia , leukocytosis with
marked lymphocytosis and eosinophilia, low serum
immunoglobulin levels, and hypoalbuminemia. Analy-
sis of T cell receptor Vβ repertoire in the periphery
showed extremely restricted heterogeneity . There
was no evidence of maternal lymphocyte engraftment
due to the result of HLA typing and FISH analysis. Fi-
nally, mutation in the RAG1 gene was detected by
DNA sequencing.11 The diagnosis of OS was estab-
lished . Immunosuppressive therapy with predniso-
lone was started and then cyclosporin A was added to
correct autoimmune manifestations. Four months af-
ter admission, the patient underwent allogeneic stem
cell transplantation (SCT) with a full matched unre-
lated cord blood unit, because no matched related do-
nor was available.12 Although the patient is infected
with Mycobacterium avium complex and received anti-
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mycobacterium therapy with ethanbutol , rifampin ,
and azithromycin, he no longer suffers from high fe-
ver and is in good condition on day + 300 post-
transplant.
So, far in Japan, six cases, including ours, of muta-
tions of recombination activating genes (RAG1 or
RAG2) were reported. As shown in Table 2, we sum-
marized clinical features and mutation sites of RAG1
and RAG2. Cases 1 and 2, which were siblings with
typical Omenn phenotype , were found to be com-
pound heterozygotes of R396C and L885R mutations
in RAG1.13 In case 3, with RAG1mutation, maternofe-
tal transplantation was detected14 as shown by Villa et
al..4 Case 4 is the only one of RAG2 mutation in Ja-
pan. Case 5 showed atypical OS without eosinophilia,
hyper-IgE, and lymphadenopathy. The case 6 (our re-
cent case) showed oligoclonal expansion of T lym-
phocytes with multiple second-site mutations leading
to typical OS with RAG1-deficient SCID11 as shown in
Figure 1. The patient is homozygous for a single base
C deletion predicted to cause frameshift and prema-
ture termination of the RAG1 protein. Six compensa-
tory second-site mutations were found in his rever-
tant T cells , which showed an activated phenotype
with a restricted TCR repertoire, expanded in periph-
eral blood, and might have contributed to the modifi-
cation of his clinical features, suggesting that the pa-
tient’s revertant T cell mosaicism is responsible for
OS phenotypes switched from T-B-SCID.
A NOVEL PHENOTYPE OF OMENN SYN-
DROME
Somatic revertant mosaicism is a rare phenomenon
that is increasingly being reported in human genetic
disorders.15,16 Both back mutations resulting in resto-
ration of wild-type sequences and second-site muta-
tions leading to compensatory changes have been re-
ported in revertant patients. Interestingly, in all cases
with somatic revertant mosaicism reported to date ,
revertant cells carried a single revertant se-
quence.15,16 It is also well recognized that revertant
mosaicism is an additional basis for milder phenotype
in several primary immunodeficiencies such as
adenosine deaminase deficiency,17 X-linked SCID,18
and Wiskott-Aldrich syndrome , 19 where revertant
lymphocytes of patients showed selective growth ad-
vantage in vivo.
From these observations, this patient is the first
case showing somatic revertant mosaicism in OS .
The present studies provide significant implications
of revertant mosaicism in the pathogenesis of OS ,
and further support the possibility that genetic rever-
sions may be more common than previously thought.
In conclusion, OS is a fatal disease if untreated.
Therapeutic options include bone marrow transplan-
tation or cord blood stem cell transplantation; how-
ever, the mortality is still 46%.7 The mortality might
be more reduced if diagnosis is established early and
treatment is initiated rapidly by using early compat-
ible bone marrow transplantation or cord blood stem
cell transplantation
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